KEY PUBLICATIONS

TatImmune top 10
(130 peer review publications in total)

  1. Cafaro A., et al. Control of SHIV89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med., 1999
  2. Cafaro A., et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol, 2000
  3. Ensoli B., et al. Prophylactic and therapeutic Phase I trials with the active Tat protein vaccine: results of the interim analysis. Antiviral Ther. 11 (Suppl. 2), International Medical Press, 2006
  4. Ensoli B., et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS, 2008.
  5. Longo O. et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine, 2009
  6. Ensoli B., et al. The preventive phase I trial with the HIV-1 Tat based vaccine. Vaccine, 2009
  7. Bellino S., et al.. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Recent Rev. Clin. Trials, 2009
  8. Ensoli F et al.. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology, 2015
  9. Ensoli B, et al.. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T-cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016
  10. Cafaro A, et al.. cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies. Expert Rev Vaccines, 2018

HSVaxTat top 10

  1. Gavioli R et al. HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity. J Immunol September 15, 2004
  2. Cellini S et al. Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. Virol J. 2008
  3. Gavioli R et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine. 2008
  4. Fanales Belasio E. et al. HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. The Journal of Immunology, 2009
  5. Nicoli F et al. The HIV-1 Tat Protein Induces the Activation of CD8+ T Cells and Affects In Vivo the Magnitude and Kinetics of Antiviral Responses, PLoS One. 2013
  6. Marconi P et al. Herpes simplex virus growth, preparation, and assay. R. Methods Mol. Biol. 2014
  7. Sicurella M, et al. An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge. PloS One. 2014
  8. Sforza F et al. HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors. AIDS. 2014
  9. Marconi P et al. Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy. Methods Mol. Biol. 2015
  10. Nicoli F et al. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine. 2016